Cargando…
Mutation of Y407 in the CH3 domain dramatically alters glycosylation and structure of human IgG
Antibody engineering is increasingly being used to influence the properties of monoclonal antibodies to improve their biotherapeutic potential. One important aspect of this is the modulation of glycosylation as a strategy to improve efficacy. Here, we describe mutations of Y407 in the CH3 domain of...
Autores principales: | Rose, Rebecca J., van Berkel, Patrick H.C., van den Bremer, Ewald T.J., Labrijn, Aran F., Vink, Tom, Schuurman, Janine, Heck, Albert J.R., Parren, Paul W.H.I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893232/ https://www.ncbi.nlm.nih.gov/pubmed/23406897 http://dx.doi.org/10.4161/mabs.23532 |
Ejemplares similares
-
Production of stable bispecific IgG1 by controlled Fab-arm exchange: Scalability from bench to large-scale manufacturing by application of standard approaches
por: Gramer, Michael J, et al.
Publicado: (2013) -
In-depth qualitative and quantitative analysis of composite glycosylation profiles and other micro-heterogeneity on intact monoclonal antibodies by high-resolution native mass spectrometry using a modified Orbitrap
por: Rosati, Sara, et al.
Publicado: (2013) -
Fab-arm exchange: What’s in a name?
por: Schuurman, Janine, et al.
Publicado: (2012) -
Opening the door to innovation
por: Schuurman, Janine, et al.
Publicado: (2014) -
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation
por: van den Bremer, Ewald TJ, et al.
Publicado: (2015)